China Dasheng Biotechnology Company
China Dasheng Biotechnology Company (CDBT) Revenue
Annual & quarterly revenue history · segment & region breakdown
CDBT · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsChina Dasheng Biotechnology Company trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-06-30 | $0.00B | -$0.02B | -100.00% |
| 2008-06-30 | $0.02B | +$0.02B | — |
| 2007-10-31 | $0.00B | -$0.00B | -100.00% |
| 2006-10-31 | $0.00B | -$0.00B | -23.13% |
| 2005-10-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income China Dasheng Biotechnology Company receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
China Dasheng Biotechnology Company reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from China Dasheng Biotechnology Company's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CDBT revenue · 4 questionsCDBT's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · China Dasheng Biotechnology Company SEC filings · GAAP · China Dasheng Biotechnology Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026